167 related articles for article (PubMed ID: 29436155)
1. Design of cyclic and d-amino acids containing peptidomimetics for inhibition of protein-protein interactions of HER2-HER3.
Pallerla S; Naik H; Singh S; Gauthier T; Sable R; Jois SD
J Pept Sci; 2018 Feb; 24(2):. PubMed ID: 29436155
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3.
Kanthala S; Gauthier T; Satyanarayanajois S
Biopolymers; 2014 Jun; 101(6):693-702. PubMed ID: 24222531
[TBL] [Abstract][Full Text] [Related]
3. Design of novel lipidated peptidomimetic conjugates for targeting EGFR heterodimerization in HER2 + cancer.
Naik H; Gauthier T; Singh S; Jois S
Bioorg Med Chem Lett; 2018 Dec; 28(22):3506-3513. PubMed ID: 30314880
[TBL] [Abstract][Full Text] [Related]
4. Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer.
Kanthala S; Banappagari S; Gokhale A; Liu YY; Xin G; Zhao Y; Jois S
Chem Biol Drug Des; 2015 Jun; 85(6):702-714. PubMed ID: 25346057
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domain.
Banappagari S; McCall A; Fontenot K; Vicente MG; Gujar A; Satyanarayanajois S
Eur J Med Chem; 2013 Jul; 65():60-9. PubMed ID: 23688700
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic.
Banappagari S; Corti M; Pincus S; Satyanarayanajois S
J Biomol Struct Dyn; 2012; 30(5):594-606. PubMed ID: 22731912
[TBL] [Abstract][Full Text] [Related]
7. Design of a doxorubicin-peptidomimetic conjugate that targets HER2-positive cancer cells.
Pallerla S; Gauthier T; Sable R; Jois SD
Eur J Med Chem; 2017 Jan; 125():914-924. PubMed ID: 27769032
[TBL] [Abstract][Full Text] [Related]
8. Design of peptidomimetics for inhibition of HER2 receptor dimerization by a combination of virtual screening, MD simulations, and QSAR in silico methods.
Jamalan M; Zeinali M; Barzegari Asadabadi E
Chem Biol Drug Des; 2013 Apr; 81(4):455-62. PubMed ID: 23006820
[TBL] [Abstract][Full Text] [Related]
9. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
10. A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models.
Singh SS; Mattheolabakis G; Gu X; Withers S; Dahal A; Jois S
Eur J Med Chem; 2021 Apr; 216():113312. PubMed ID: 33667849
[TBL] [Abstract][Full Text] [Related]
11. A peptidomimetic with a chiral switch is an inhibitor of epidermal growth factor receptor heterodimerization.
Kanthala SP; Liu YY; Singh S; Sable R; Pallerla S; Jois SD
Oncotarget; 2017 Sep; 8(43):74244-74262. PubMed ID: 29088782
[TBL] [Abstract][Full Text] [Related]
12. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
13. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines.
Banappagari S; Ronald S; Satyanarayanajois SD
Medchemcomm; 2011 Jan; 2(8):752-759. PubMed ID: 21887403
[TBL] [Abstract][Full Text] [Related]
15. A conformationally constrained peptidomimetic binds to the extracellular region of HER2 protein.
Banappagari S; Ronald S; Satyanarayanajois SD
J Biomol Struct Dyn; 2010 Dec; 28(3):289-308. PubMed ID: 20919746
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and docking studies of peptidomimetics based on HER2-herceptin binding site with potential antiproliferative activity against breast cancer cell lines.
Satyanarayanajois S; Villalba S; Jianchao L; Lin GM
Chem Biol Drug Des; 2009 Sep; 74(3):246-57. PubMed ID: 19703026
[TBL] [Abstract][Full Text] [Related]
17. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
Sakai K; Yokote H; Murakami-Murofushi K; Tamura T; Saijo N; Nishio K
Cancer Sci; 2007 Sep; 98(9):1498-503. PubMed ID: 17627612
[TBL] [Abstract][Full Text] [Related]
18. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
19. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.
Schaefer G; Shao L; Totpal K; Akita RW
Cancer Res; 2007 Feb; 67(3):1228-38. PubMed ID: 17283159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
